Objective: Patients with cancer tend to develop hematological and immunological alterations during the disease process. Medicinal fungi can stimulate the immune and hematopoietic systems, promoting improvements in the prognosis and physiological response. In this trial it is aimed to evaluate changes in hematological and immunological parameters in patients with breast cancer undergoing chemotherapy after dietary supplementation with Agaricus sylvaticus. Method: A randomized, double-blind, placebocontrolled study was carried out. 46 patients (stadiums II and III), were randomly assigned to receive either: nutritional supplement with A. sylvaticus (2.1 g/day) or placebo. Patients received three cycles (n=26) and six cycles (n=20) of chemotherapy. Clinical and laboratory evaluations were performed. The results were analyzed using Microsoft Excel 2003 and R-version 2.11.1, significant results at p≤ 0.05.
Breast cancer is the most prevalent malignant cancer among women worldwide. Based on confidence data from the Brazilian Ministry of Health the experts estimate the existence of more than 49.000 new cases in Brazil annually both 2010 and 2011. Urbanization, increasing access to education and, health care is directly associated with improvement of breast cancer notification and management (1) (2) (3) .
It is well known that treatment for breast cancer is complex and varies according to the histological diagnosis, age, clinical management, treatment, surgery and staging of the disease (4) (5) (6) . Factors associated with tumor growth and chemotherapy can cause functional damage mainly in the hematological and immune systems of this patients.
It is important, additionally, to consider the side effects caused by conventional cancer treatments because could reduce significantly the caloric intake and absorption of nutrients, complicating treatment and reducing quality of life (7) (8) (9) (10) (11) .
Chemotherapy is a treatment method widely used to treat breast cancer. The therapy aims at striking cell populations in different phases of the cell cycle, interfering with the reproduction, eliminating the hidden spread of the disease. However, during treatment, chemotherapy can also destroy normal cells and cause serious side effects (7) (8) .
The most serious complication of chemotherapy is bone marrow suppression, with consequent worsening of hematological and immunological patterns that lead to systemic infection, coagulation disorders, amenorrhea and ovarian failure (6) (7) (8) (9) (10) (11) .
Different studies have suggested that the Agaricus sylvaticus mushroom, a fungus from the Agaricaceae family, has modulatory substances such as lectin, β-Glucan, proteoglucans, ergosterol, and arginine.
The use of A. sylvaticus as adjuvant therapy to conventional treatment has showed promising results improving the quality of life of cancer patients (12) (13) (14) (15) (16) (17) .
The use of A. sylvaticus fungus as a dietary supplement in patients with various types of cancer has been studied (1) (2) . Although it's active mechanism is not clear yet (3) , researchers have shown that the use of this mushroom acts to inhibit tumor growth and stimulate the hematological and immunological systems (12) (13) (14) (15) (16) (17) . 
Inclusion criteria
Only women among 40 and 65 years old with breast cancer in stadiums II or III undergoing chemotherapy were included.
Ethics
The research process was approved by the Ethics 
RESULTS

After six months of attendance at the Oncology
Clinic of the Federal District Hospital, 46 patients with breast cancer completed the study; they were separated according to chemotherapy cycles and later on placebo or study groups.
Results of Patients with three chemotherapy cycles
Patients with three chemotherapy cycles after allocation into placebo or study groups presented the there was a significant increase in red blood cell count, hematocrit, corpuscular hemoglobin concentration, leukocyte, monocytes and total lymphocyte count after three months of supplementation (Table 1) .
When comparing the first and third months of chemotherapy, considering reference values from 3.9 to 5.03 / mm 3 for evaluation of red blood cells, the placebo group showed significant decrease (from 4.47 ± 0.04 / mm 3 to 4.14 ± 0.53, p = 0.02), while the supplemented group showed significant blood cell increase (of 4:31 ± 0.29 / mm 3 to 4.76 ± 0.58, p = 0, 2003) ( Table 1) . In relation to values of mean corpuscular hemoglobin concentration (MCHC) there was a significant difference for the A. sylvaticus group. There was an increase in MCHC values when comparing the first and last months of supplementation (from 32.46 ± 1.11 to 34.94 ± 2.1, p = 0.001). As for the placebo group there was no significant decrease (from 34.55 ± 3.81 to 33.67 ± 1.72, p = 0.45) ( Table 1) .
AGARICUS SYLVATICUS FUNGUS AND BREAST CANCER PATIENTS
Regarding immunological parameters, the number of white blood cells was observed. There was a significant increase in the number of leukocytes (5.07 ± 1.54 to 5.9 ± 1.90, p = 0.03) for the A. sylvaticus group. Findings in the placebo group showed a slight decrease, but revealed no significant difference (5.28 ± 1.70 to 4.36 ± 1.55, p = 0.26). Observed reference values were 3.5 to 10.5 / mm 3 ( Table 2) .
The values of myeloid elements found revealed a significant increase only in the number of monocytes for group A. sylvaticus (5.67 ± 1.76 7.007 ± 1.41, p = 0.001) and placebo (5.59 ± 1.50 to 7.89 ± 2.46, p = 0.01). Regarding neutrophiles, eosinophiles, and basophiles there was no significant difference for both groups ( were in stadium II and 60% (n=6) in stadium III of disease.
Data analysis was performed on two times. Initially first and third month's chemotherapy was compared.
After that a comparative analysis was performed between the first and sixth month of observation.
This evaluation was performed for placebo and
A. sylvaticus groups.
Regarding CBC results, the group supplemented with A. sylvaticus, showed significant levels of red blood cells, hemoglobin, hematocrit, mean (Table 3) .
With respect to immunological parameters, the white blood cells count series was observed.
Regarding leukocyte numbers, there was a significant increase in the last month of supplementation for the A. sylvaticus group (4.7 ± 1.4 / mm 3 to 5.95 ± 1.23 /mm 3 , p=0.008). Compared to the placebo group, there was a significant reduction in the number of leukocytes in the third month of supplementation (4.51 ± 1.05 /mm 3 to 3.14 ± 055/mm 3 , p=0.004).
Observed reference values were 3.5 to 10.5 /mm 3 ( Table 4 ).
The percentage values of myeloid elements found for the A. sylvaticus group revealed significant results in the number of neutrophils (from 46.17 ± 13.19% to 54.5 ± 10.3%, p=0.01). For the placebo group, there was but a significant decreases in the percentage of basophiles (0.8 ± 0.4% to 0.2 ± 0.4%, p=0.005). As for data on eosinophiles and monocytes, neither group showed any difference ( (Table 4 ).
Platelets showed no significant values for the placebo group or the A. sylvaticus group in relation to the survey follow-up period ( Table 4 ). In the current study, with respect to the blood count of patients undergoing three chemotherapy cycles, data analysis revealed a significant increase in hematocrit serum levels (p=0.04), and hemoglobin (p=0.03), MCHC (p=0.001) in the group treated with A. sylvaticus after three months of supplementation.
DISCUSSION
These findings were not observed in patients included in the placebo group which showed a significant reduction (p=0.02) in the number of red blood cells ( Moreover, the decrease in lymphocyte count is also associated with more aggressive tumor behavior (14) . The mechanism of action of these fungi and their bioactive molecules in cancer therapy need to be better clarified; nevertheless, research has shown that many of these substances exert an anticarcinogenic, antiviral, antithrombotic, antibiotic and antiinflammatory further to many more functions that provide health benefits (12) (13) (14) (15) (16) (17) 
